It is showing results and they have large sample. Look at the sample size - AVXL does not stand any chance to even consider going to FDA for approval. They will need at least one large trial (LLY has 2 trials going on)
In short - add 4 to 5 years for AD approval - Missling will milk the company and make money
—-
In the primary analysis population (n=1182), the main goal (iADRS) showed 35% slowing of decline, compared to placebo.
Meanwhile, an important secondary goal (Clinical Dementia Rating-Sum of Boxes (CDR-SB) - a measure of disease severity) showed 36% slowing of decline over 18 months.
News 
Market Data 
Discover 
